Telix Pharmaceuticals Ltd
ASX:TLX
Telix Pharmaceuticals Ltd
ASX:TLX
Price:
14.97 AUD
-0.53%
Market Closed
Updated:
May 7, 2024
Section:
Relative Value
The Relative Value of one
TLX
stock under the Base Case scenario is
13.64
AUD.
Compared to the current market price of 14.97 AUD,
Telix Pharmaceuticals Ltd
is
Overvalued by 9%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TLX
Relative Value
Base Case
13.64
AUD
Overvaluation 9%
Valuation Multiples
Multiples Across Competitors
TLX Competitors Multiples
Telix Pharmaceuticals Ltd Competitors
Telix Pharmaceuticals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
4.8B AUD | 9.6 | 930 | 269.1 | 269.1 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
288.1B USD | 5.3 | 59.8 | 13 | 19.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
162.1B USD | 5.5 | 43.1 | 18.3 | 30.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.9B USD | 8.1 | 27.4 | 22.2 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
104.8B USD | 10.7 | 29.1 | 23.2 | 24.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.7B USD | 3 | 169.1 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46B USD | 8.9 | -7.7 | -8.3 | -7.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.9B USD | 3.3 | 27.2 | 14 | 17.5 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.2 | 46 | 63.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
